Brian T Hill
Overview
Explore the profile of Brian T Hill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
6491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hill B, Ma S, Zent C, Baran A, Wallace D, Advani A, et al.
Blood Adv
. 2023 Oct;
8(2):378-387.
PMID: 37871300
Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but...
12.
Rezazadeh A, Szabo A, Khurana A, Inwards D, Lunning M, Bartlett N, et al.
Haematologica
. 2023 Oct;
109(5):1439-1444.
PMID: 37855051
Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT...
13.
Rogness V, Wei W, Cortese M, Hill B
Leuk Res
. 2023 Oct;
134:107402.
PMID: 37778305
No abstract available.
14.
Aleixo G, Wei W, Chen P, Gandhi N, Anwer F, Dean R, et al.
Bone Marrow Transplant
. 2023 Sep;
58(12):1384-1389.
PMID: 37699993
Recently there has been a growing interest in evaluating body composition as a marker for prognosis in cancer patients. The association of body composition parameters and outcomes has not been...
15.
Sauter C, Hill B
Transplant Cell Ther
. 2023 Jul;
29(7):408-409.
PMID: 37400191
No abstract available.
16.
Wallace D, Rowland C, Hill B, Baran A, Casulo C, Reagan P, et al.
Leuk Lymphoma
. 2023 Jun;
64(9):1579-1582.
PMID: 37341984
No abstract available.
17.
Mishra R, Dima D, Kumar S, Mian A, Taneja A, Karna R, et al.
Hematol Oncol
. 2023 Jun;
41(5):884-893.
PMID: 37309225
With improvement in survival after chronic lymphocytic leukemia (CLL) diagnosis, the real-world burden of second hematological malignancies (SHM) has not been comprehensively assessed in recent era. We analyzed risk, incidence,...
18.
Nichols M, Ondrejka S, Patil S, Durkin L, Hill B, Hsi E
Leuk Lymphoma
. 2023 May;
64(8):1433-1441.
PMID: 37226602
Follicular lymphoma (FL) is a common, indolent small B-cell lymphoma. While the Follicular Lymphoma International Prognostic Index is widely used, reliable prognostic and predictive biomarkers are needed. A recent study...
19.
Shadman M, Manzoor B, Sail K, Tuncer H, Allan J, Ujjani C, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Apr;
23(7):515-526.
PMID: 37076367
Introduction: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings. Materials And Methods: Using deidentified...
20.
Major A, Yu J, Shukla N, Che Y, Karrison T, Treitman R, et al.
Blood Adv
. 2023 Apr;
7(16):4528-4538.
PMID: 37026796
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy...